Discovery, Characterization, and Engineering of LvIC, an α4/4-Conotoxin That Selectively Blocks Rat α6/α3β4 Nicotinic Acetylcholine Receptors
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Xiaopeng Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Guangxi University, Nanning 530004, China. Hauptthemen laut MEDLINE: Conotoxins, Receptors, Nicotinic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Ministry of Science and Technology of the People's Republic of China, National Health and Medical Research Council, Australian Research Council.
Abstract (Originalsprache)
α6β4 nicotinic acetylcholine receptors (nAChRs) are expressed in the central and peripheral nervous systems, but their functions are not fully understood, largely because of a lack of specific ligands. Here, we characterized a novel α-conotoxin, LvIC, and designed a series of analogues to probe structure-activity relationships at the α6β4 nAChR. The potency and selectivity of these conotoxins were tested using two-electrode voltage-clamp recording on nAChR subtypes expressed in Xenopus laevis oocytes. One of the analogues, [D1G,ΔQ14]LvIC, potently blocked α6/α3β4 nAChRs (α6/α3 is a chimera) with an IC50 of 19 nM, with minimal activity at other nAChR subtypes, including the structurally similar α6/α3β2β3 and α3β4 subtypes. Using NMR, molecular docking, and receptor mutation, structure-activity relationships of [D1G,ΔQ14]LvIC at the α6/α3β4 nAChR were defined. It is a potent and specific antagonist of α6β4 nAChRs that could potentially serve as a novel molecular probe to explore α6β4 nAChR-related neurophysiological and pharmacological functions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, Guangxi University, Nanning 530004, China.
- Center for Novel Target and Therapeutic Intervention, Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, China.
- Institute for Molecular Bioscience, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Queensland, Brisbane 4072, Queensland, Australia.
- Key Laboratory of Tropical Biological Resources of Ministry of Education, Hainan University, Haikou 570228, China.
ORCID-Profile: Xiaopeng Zhu, Quentin Kaas, Peta J Harvey, David J Craik, Sulan Luo
Förderung
- Ministry of Science and Technology of the People's Republic of China
- National Health and Medical Research Council
- Australian Research Council
- National Natural Science Foundation of China
- Higher Education Discipline Innovation Project
- Science and Technology Department of Guangxi Zhuang Autonomous
Zitieren
APA
Zhu, X., Wang, S., Kaas, Q., Yu, J., Wu, Y., Harvey, P. J., Zhangsun, D., Craik, D. J., & Luo, S. (2023). Discovery, Characterization, and Engineering of LvIC, an α4/4-Conotoxin That Selectively Blocks Rat α6/α3β4 Nicotinic Acetylcholine Receptors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01786
Vancouver
Zhu X, Wang S, Kaas Q, Yu J, Wu Y, Harvey PJ, et al. Discovery, Characterization, and Engineering of LvIC, an α4/4-Conotoxin That Selectively Blocks Rat α6/α3β4 Nicotinic Acetylcholine Receptors. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01786
BibTeX
@article{Zhu2023,
author = {Zhu, Xiaopeng and Wang, Shuai and Kaas, Quentin and Yu, Jinpeng and Wu, Yong and Harvey, Peta J and Zhangsun, Dongting and Craik, David J and Luo, Sulan},
title = {Discovery, Characterization, and Engineering of LvIC, an α4/4-Conotoxin That Selectively Blocks Rat α6/α3β4 Nicotinic Acetylcholine Receptors},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01786}
}
EUVIMED